Nevada ePro #41NHA-S4034

RFI for Medicaid Pharmaceutical Data and Retrospective Pricing Analytics SaaS

The Nevada Health Authority is gathering information on a SaaS platform to support Medicaid prescription-drug analytics and preferred drug list decisions. - Government buyer: Nevada Health Authority; Nevada Medicaid – Prescription Drug Rebate. No specific office is identified. - Opportunity type: Informational-only RFI seeking platform information and projected costs; it is not a request for bids or proposals and does not anticipate a contract award. - Requested service: Pharmaceutical data and retrospective pricing analytics SaaS to support single preferred drug list management, fiscal forecasting, formulary and clinical strategy, and contracting and market-access decisions. - Requested capabilities: Track drug and biologic lifecycles, brand/generic/biosimilar launches, loss of exclusivity, clinical pipelines, litigation, and regulatory impacts; provide market and clinical reports, alerts, new-drug reviews, expert consultation, and pricing and financial forecasts; validate HCPCS/CPT drug codes and provide coding, billing, and reimbursement information. - Notable requirements: Support Medicaid-focused analysis, transparent forecast inputs, catalyst alerts, scorecards, analogs, and expert commentary, with web access available around the clock. - OEMs and vendors: No OEM, software product, or vendor is named in the opportunity documents. - Service line classifications: Three SaaS service lines are listed, each with a quantity of 1, under NIGP 920-03, 920-45, and 208-57.

Description

This is a Request for Information (RFI) for a SaaS platform providing pharmaceutical data and retrospective pricing analytics for Nevada Health Authority, Medicaid - Prescription Drug Rebate. The platform is described as combining pharmaceutical market, clinical pipeline, pricing, and medical/pharmacy benefit information to support preferred drug list management, forecasting, and formulary, clinical, contracting, and market-access decisions. Requested capabilities include drug and biologic lifecycle tracking, loss-of-exclusivity and launch insights, clinical and pricing reports, alerts, forecasts, and drug-code validation. Vendors are asked to provide projected costs; this RFI is informational only and will not result in a contract award.

View original listing